Emcure Pharmaceuticals Limited, incorporated in 1981, is a leading Indian pharmaceutical company engaged in the development, manufacturing, and global marketing of a diverse range of pharmaceutical products across multiple therapeutic areas. Ranked 13th in domestic sales and 4th in market share in covered markets for MAT September 2023, Emcure is a leader in the gynaecology and HIV antiviral segments. With domestic sales contributing over 50% of total revenue and growing at a CAGR of 10.80% between September 2019 and September 2023, the company has outpaced the Indian pharmaceutical market. It operates five research facilities in India, employing 552 scientists and filing over 1,800 global regulatory documents, including 201 granted patents. Emcure's 13 manufacturing facilities in India produce a wide range of pharmaceutical and biopharmaceutical products, including chiral molecules, iron molecules, and cytotoxic substances. Supported by over 5,000 field personnel and 5,000 stockists across 37 carry-and-forward agents, the company maintains an extensive marketing and distribution network, ensuring strong engagement with healthcare providers and efficient product availability.